\
&
Contact us
\
&
Contact us
Published on | 2 months ago
ProgrammesThe European High Performance Computing Joint Undertaking (EuroHPC JU) has announced two new opportunities in the field of HPC:
The objective of this call is to develop a new set of appropriate metrics and benchmarks for the next generation of EuroHPC infrastructure. The call addresses two topics:
A European HPC-centric Benchmarking Framework
A European Benchmarking Framework for hybrid quantum-classical computing
Deadline to submit proposals is 24 March 2026. More information is available on the EuroHPC website.
The Frontier AI Grand Challenge is a major EU-wide initiative launched by the European Commission and the EuroHPC Joint Undertaking. Its primary mission is to bridge the strategic gap in high-end AI development by fostering the creation of sovereign, large-scale European AI models.
The expected outcome of the Frontier AI Grand Challenge is the selection of one proposal to train a frontier AI model that will outperform state-of-the-art models in a number of relevant tasks.
Deadline to submit proposals is 13 April 2026. More information is available on the challenge's website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
